| Name | Darovasertib |
| Description | Darovasertib (LXS196) is a potent, selective, and orally active protein kinase C (PKC) inhibitor with IC50 values of 1.9 nM for PKCα, 0.4 nM for PKCθ, and 3.1 μM for GSK3β. |
| In vitro | An orally available protein kinase C (PKC) inhibitor with potential immunosuppressive and antineoplastic activities. Upon oral administration, protein kinase C inhibitor Darovasertib binds to and inhibits PKC, which prevents the activation of PKC-mediated signaling pathways. This may lead to the induction of cell cycle arrest and apoptosis in susceptible tumor cells. PKC, a serine/threonine protein kinase overexpressed in certain types of cancer cells, is involved in tumor cell differentiation, proliferation, invasion and survival. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 16.67 mg/mL (35.28 mM), Sonication is recommended. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 4 mg/mL (8.47 mM), Sonication is recommended.
|
| Keywords | Protein kinase C | PKC | LXS-196 | LXS 196 | Inhibitor | inhibit | IDE-196 | IDE196 | IDE 196 | Darovasertib |
| Inhibitors Related | PKN1/2-IN-1 | Forskolin | Ellagic acid | α-Vitamin E | Ro-3306 | Staurosporine | Methyl-Hesperidin | Gondoic acid | Miltefosine | Fasudil hydrochloride | Mitoxantrone dihydrochloride | R59949 |
| Related Compound Libraries | Failed Clinical Trials Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Kinase Inhibitor Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Clinical Compound Library | Bioactive Compounds Library Max | TGF-beta/Smad Compound Library | Anti-Cancer Drug Library | Anti-Cancer Active Compound Library |